Of note, the in vitro suppressive function of Treg from SLE patients was not impaired suggesting that expansion of the endogenous Treg population by low-dose IL-2 therapy is a feasible approach to strengthen immune tolerance. The gene discussed is IL2; the disease is systemic lupus erythematosus.